IP Library Granted Patent US 10,111,889
Granted Patent B2
US 10,111,889 · App. 15/460,382 · Granted Oct 30, 2018

Uses of ganaxolone

Inventors: Mathew Victor Jones (Madison, WI); Chiara Cirelli (Verona, WI); Kile Patrick Mangan (Madison, WI); Aaron B. Nelson (New York, NY)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
A61K31/57A61K49/0008C12Q1/68C12Q1/6883C12Q2600/106C12Q2600/156C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,889
App. No.
15/460,382
Granted
Oct 30, 2018
Kind
B2
Abstract

Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects. In addition, ganaxolone therapy is particularly useful in subjects with absence epilepsy characterized by a reduction in tonic inhibition. Low dose ganaxolone is also used to reduce sleep disruptions and to treat sleep disorders in subjects in need of such treatment.

Claims (5)

1. A method of treating sleep disruptions due to absence epilepsy in a mammalian subject in need thereof, comprising administering ganaxolone to the mammalian subject in an amount of 0.2 to 2 mg/kg per dose, wherein the epilepsy is characterized by a deficit in tonic inhibition.

2. The method of claim 1 , wherein administration of ganaxolone restores durations of non-REM and intensity of slow wave activity toward normal levels.

3. The method of claim 1 , wherein administration of ganaxolone reduces the number of brief awakenings, improves the REM/non-REM sleep cycle, or both.

4. The method of claim 1 , wherein the mammalian subject has a γ2R43Q mutation in the GABA A receptor.

5. The method of claim 1 , wherein the mammalian subject is a human subject.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 3, 2018
From: UNIVERSITY OF WISCONSIN MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046483/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2017
From: JONES, MATHEW; NELSON, AARON; MANGAN, KILE; CIRELLI, CHIARA
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 041847/0763 →
Continuity (3)
Division 14718524 · May 21, 2015
Provisional Application 62001347 · May 21, 2014
Related Publication 20170182061A1 · Jun 29, 2017